EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
Market Cap & Net Worth: EQL PHARMA AB (7JK)
EQL PHARMA AB (F:7JK) has a market capitalization of $153.68 Million (€149.72 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #17727 globally and #1854 in its home market, demonstrating a 1.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EQL PHARMA AB's stock price €5.07 by its total outstanding shares 29529610 (29.53 Million).
EQL PHARMA AB Market Cap History: 2021 to 2026
EQL PHARMA AB's market capitalization history from 2021 to 2026. Data shows growth from $109.73 Million to $153.68 Million (7.91% CAGR).
EQL PHARMA AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EQL PHARMA AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 7JK by Market Capitalization
Companies near EQL PHARMA AB in the global market cap rankings as of March 19, 2026.
Key companies related to EQL PHARMA AB by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
EQL PHARMA AB Historical Marketcap From 2021 to 2026
Between 2021 and today, EQL PHARMA AB's market cap moved from $109.73 Million to $ 153.68 Million, with a yearly change of 7.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €153.68 Million | -5.06% |
| 2025 | €161.86 Million | -21.47% |
| 2024 | €206.12 Million | +143.73% |
| 2023 | €84.57 Million | +6.08% |
| 2022 | €79.72 Million | -27.35% |
| 2021 | €109.73 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of EQL PHARMA AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $153.68 Million USD |
| MoneyControl | $153.68 Million USD |
| MarketWatch | $153.68 Million USD |
| marketcap.company | $153.68 Million USD |
| Reuters | $153.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.